• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Genmab A/S

    5/15/26 1:05:26 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GMAB alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    GENMAB A/S

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    K3967W102

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    K3967W102


    1Names of Reporting Persons

    ORBIS INVESTMENT MANAGEMENT LTD
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    BERMUDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,549,674.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    3,549,674.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,549,674.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.5 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP Number(s):
    K3967W102


    1Names of Reporting Persons

    Allan Gray Australia Pty Ltd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    AUSTRALIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    7,810.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    7,810.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,810.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    GENMAB A/S
    (b)Address of issuer's principal executive offices:

    TOLDBODGADE 33, Copenhagen, DENMARK 1253
    Item 2. 
    (a)Name of person filing:

    ORBIS INVESTMENT MANAGEMENT LTD Allan Gray Australia Pty Ltd
    (b)Address or principal business office or, if none, residence:

    ORBIS INVESTMENT MANAGEMENT LTD: Orbis House, 25 Front Street, Hamilton, Bermuda HM11 Allan Gray Australia Pty Ltd: Level 2, Challis House, 4 Martin Place, Sydney NSW2000, Australia
    (c)Citizenship:

    ORBIS INVESTMENT MANAGEMENT LTD - BERMUDA Allan Gray Australia Pty Ltd - AUSTRALIA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    K3967W102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Equivalent to an IA.
    Item 4.Ownership
    (a)Amount beneficially owned:

    3,557,484
    (b)Percent of class:

    5.5  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    ORBIS INVESTMENT MANAGEMENT LTD - 3,549,674 Allan Gray Australia Pty Ltd - 7,810

     (ii) Shared power to vote or to direct the vote:

    ORBIS INVESTMENT MANAGEMENT LTD - 0 Allan Gray Australia Pty Ltd - 0

     (iii) Sole power to dispose or to direct the disposition of:

    ORBIS INVESTMENT MANAGEMENT LTD - 3,549,674 Allan Gray Australia Pty Ltd - 7,810

     (iv) Shared power to dispose or to direct the disposition of:

    ORBIS INVESTMENT MANAGEMENT LTD - 0 Allan Gray Australia Pty Ltd - 0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Other persons have the right to receive dividends from, the power to direct the receipt of dividends from, or the right to receive the proceeds from the sale of, the securities of the issuer identified in Item 4(a) that are beneficially owned by Orbis Investment Management Ltd. Another person has the right to receive dividends from, the power to direct the receipt of dividends from, or the right to receive the proceeds from the sale of, the securities of the issuer identified in Item 4(a) that are beneficially owned by Allan Gray Australia Pty Ltd.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    Information with respect to each of Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd (collectively, the "Reporting Persons") is given solely by each such Reporting Person and no Reporting Person has responsibility for the accuracy or completeness of information supplied by any other Reporting Person. Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd are classified as a Non-U.S. Institution (FI) that is equivalent to an Investment Adviser (IA). Notwithstanding that the Reporting Persons are making this filing together, none of the Reporting Persons represents that it is a member of a group for the purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended. Each Reporting Person disclaims beneficial ownership of any shares beneficially owned by any other Reporting Person as specified in Item 4(a).
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    ORBIS INVESTMENT MANAGEMENT LTD
     
    Signature:Matthew Gaarder
    Name/Title:Attorney-in-Fact
    Date:05/15/2026
     
    Allan Gray Australia Pty Ltd
     
    Signature:Matthew Gaarder
    Name/Title:Attorney-in-Fact
    Date:05/15/2026
    Get the next $GMAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GMAB

    DatePrice TargetRatingAnalyst
    5/27/2026$40.00Buy
    Truist
    4/22/2026Neutral → Buy
    Goldman
    3/27/2026$32.00Outperform
    Wolfe Research
    3/2/2026$40.00Overweight
    Wells Fargo
    2/17/2026$41.50Buy
    Jefferies
    2/17/2026$34.00Equal-Weight
    Morgan Stanley
    9/23/2025$43.00Neutral → Buy
    Guggenheim
    4/1/2025Mkt Perform → Underperform
    Bernstein
    More analyst ratings

    $GMAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Genmab A/S bought $102,411,048 worth of shares (1,055,784 units at $97.00) (SEC Form 4)

    4 - GENMAB A/S (0001434265) (Reporting)

    12/30/25 5:41:44 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GMAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress

    Twenty-three abstracts will highlight the versatility and strength of Genmab's portfolio and pipeline, including data from the comprehensive epcoritamab development program, including 4 oral presentations Three abstracts will show the ongoing clinical trial evaluations of the safety and efficacy of Genmab's investigational late-stage medicines, rinatabart sesutecan and petosemtamab Data evaluating epcoritamab will demonstrate outcomes across monotherapy, combination regimens and fixed-duration use, including outpatient administration and use in earlier lines of treatment Genmab A/S (NASDAQ:GMAB) announced today that 23 abstracts, including 20 abstracts evaluating epcoritamab, a su

    5/21/26 5:00:00 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Major Shareholder Announcement

    Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; May 8, 2026 – Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that through shares, as of May 8, 2026, Orbis Investment Management Limited controlled the voting rights to 3,166,357 shares in Genmab A/S, which amounts to 5.08% of the share capital and voting rights in Genmab A/S.   The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people with c

    5/8/26 3:05:12 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Major Shareholder Announcement

    Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of April 13, 2026, Orbis Investment Management Limited through shares controlled the voting rights to 3,114,318 shares in Genmab A/S, which amounts to 4.85% of the share capital and voting rights in Genmab A/S.   The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people

    4/14/26 10:44:22 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GMAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Genmab A/S bought $102,411,048 worth of shares (1,055,784 units at $97.00) (SEC Form 4)

    4 - GENMAB A/S (0001434265) (Reporting)

    12/30/25 5:41:44 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Genmab A/S claimed ownership of 71,463,077 shares (SEC Form 3)

    3 - GENMAB A/S (0001434265) (Reporting)

    12/18/25 5:49:12 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Genmab with a new price target

    Truist initiated coverage of Genmab with a rating of Buy and set a new price target of $40.00

    5/27/26 8:15:52 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab upgraded by Goldman

    Goldman upgraded Genmab from Neutral to Buy

    4/22/26 7:43:03 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Genmab with a new price target

    Wolfe Research initiated coverage of Genmab with a rating of Outperform and set a new price target of $32.00

    3/27/26 8:48:55 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GMAB
    SEC Filings

    View All

    SEC Form 6-K filed by Genmab A/S

    6-K - GENMAB A/S (0001434265) (Filer)

    5/29/26 4:41:28 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Genmab A/S

    SCHEDULE 13G/A - GENMAB A/S (0001434265) (Subject)

    5/15/26 1:05:26 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Genmab A/S

    6-K - GENMAB A/S (0001434265) (Filer)

    5/13/26 10:15:32 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GMAB
    Leadership Updates

    Live Leadership Updates

    View All

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines

    Company Announcement COPENHAGEN, Denmark; February 22, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that Tahamtan Ahmadi, M.D., Ph.D., has been appointed to the newly created position of Executive Vice President and Chief Medical Officer, Head of Experimental Medicines effective March 1, 2021. Dr. Tahi Ahmadi joined Genmab in 2017 and previously served as Genmab’s Senior Vice President, Head of Oncology. In this new role, Dr. Ahmadi will lead research, discovery, regulatory and medical activities. He joins the Executive Management Team of Chief Executive Officer Dr. Jan van de Winkel, Chief Development Officer Dr. Judith Klimovsky, Chief Financial Officer Anthony Pagano, and Chief Opera

    2/22/21 8:00:51 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Genmab A/S (Amendment)

    SC 13G/A - GENMAB A/S (0001434265) (Subject)

    2/8/24 10:03:08 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Genmab A/S (Amendment)

    SC 13G/A - GENMAB A/S (0001434265) (Subject)

    2/2/24 2:18:06 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genmab A/S

    SC 13G - GENMAB A/S (0001434265) (Subject)

    2/6/23 2:36:15 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GMAB
    Financials

    Live finance-specific insights

    View All

    Genmab Publishes 2025 Annual Report

    Company Announcement COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (NASDAQ:GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025, financial performance for the year and the financial outlook for 2026. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company's website, www.genmab.com/investor-relations. Conference CallGenmab will hold a conference call to discuss the full year results for 2025 today, February 17, 2026 at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST. To join the call please use the below registration link. Registered participants will receive an email w

    2/17/26 11:01:23 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

    Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-st

    9/29/25 1:14:00 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

    Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark; UTRECHT, The Netherlands; September 29, 2025, – Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus,

    9/29/25 1:08:26 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care